Linked Life Data

6104634

Source:http://linkedlifedata.com/resource/pubmed/id/6104634

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1980-9-26
pubmed:abstractText
The acute and chronic circulatory effects of a new beta adrenergic blocking drug, dl-1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol hydrochloride, GYKI-41099, have been assessed in patients with hyperkinetic circulation/or mild hypertension. The acute effects of GYKI-41099 2.5, 5 and 10 mg have been compared with those of propranolol 10, 20 and 40 mg using a cross-over design in 18 patients with elevated cardiac index. Each dose of both drugs produced a significant reduction in sitting and exercise heart rate. The potency of GYKI-41099 compared with propranolol proved to be 3:1. 13 patients with hyperkinetic circulation on GYKI-41099 5-15 mg daily for 2 months exhibited a significant reduction in resting heart rate and cardiac index. In 13 patients with mild hypertension the drug exerted marked antihypertensive effect. Side effects were minimal and short-lived.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0174-4879
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
200-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
Clinical-pharmacological evaluation of a new beta blocker, GYKI-41099 (tobanum).
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial